A clinical trial involving thymosin alpha-1, also known as thymalfasin, was updated to completed status as of June 18, 2026. The trial, registered as NCT06024356, is titled "Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer." The study evaluated a combination approach using neoadjuvant chemoradiotherapy, a PD-1 inhibitor, and thymalfasin in patients with locally advanced mid-low rectal cancer.
The trial registry lists the current status as completed, with no phase designation provided in the available record. This update reflects only the change in trial status and does not include any reported outcomes or results data. Thymosin alpha-1 remains classified as an unapproved compound under research investigation and has not received regulatory approval for this or other indications.
Readers should note that a completed status indicates the trial has concluded its planned activities, but it does not by itself confirm whether the treatment combination was effective or safe. No efficacy or safety conclusions can be drawn from this status update alone. Additional details, including any published results, may become available through the official clinical trial registry listed in the source link. For more background on this compound, see the linked compound overview.